Gene Therapy Market
Gene Therapy Market Study by Lentivirus, Adeno-Associated Virus, Retrovirus & Gamma Retrovirus, Modified Herpes Simplex Virus, Adenovirus, Non-viral Plasmid Vector from 2024 to 2034
Analysis of Gene Therapy Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Gene Therapy Market Outlook (2024 to 2034)
The global gene therapy market size is calculated at a value of US$ 10.34 billion in 2024. Increasing cases of rare diseases is contributing to the rising need for cell and gene therapies. Expanding at a CAGR of 14.1%, the market is forecasted to reach US$ 38.52 billion by the end of 2034.
Ex-vivo gene therapy is becoming more popular for neurological treatments, which is expected to drive gene therapy market growth through 2034. Over the last few years, the world has seen a significant increase in focus on healthcare, which is resulting in a massive surge in research and development activities.
Increasing use of gene modification in a variety of treatments, as well as the rising use of genome editing in biotechnology applications, are also expected to boost the demand for advanced gene therapies in the coming 10 years. Genetic testing plays a vital role in preventive healthcare driven by its rising awareness and knowledge among people. The rising prevalence of chronic disorders is boosting the use of genetic testing technologies. Furthermore, the growing popularity of DNA testing is generating profitable opportunities for genealogy product and service providers.
Gene delivery systems can effectively improve the treatment procedure and lead to effective results. Cell and gene therapies are expected to be vital in the treatment of diabetes, cancer, and cardiovascular diseases. Also, as the prevalence of hyperthyroidism and other chronic disorders is increasing in newborns, parents are widely opting for genetic testing services.
- The East Asian gene therapy market size is forecasted to reach US$ 8.42 billion by 2034.
- North America is estimated to account for 34.8% of the global gene therapy market share by 2034.
| Report Attribute | Detail |
|---|---|
| Gene Therapy Market Size (2024E) | US$ 10.34 Billion |
| Forecasted Market Value (2034F) | US$ 38.52 Billion |
| Global Market Growth Rate (2024 to 2034) | 14.1% CAGR |
| South Korea Market Value (2034F) | US$ 2 Billion |
| India Market Growth Rate (2024 to 2034) | 22.4% CAGR |
| Key Companies Profiled | American Gene Technologies; BioMarin; Bluebird Bio Inc.; Orchard Therapeutics Limited; uniQure NV; BioNTech; Oxford Biomedica Plc.; Celgene Corporation; Shanghai Sunway Biotech Co., Ltd.; Sibiono GeneTech Co. Ltd.; Biogen; Dendreon Pharmaceuticals LLC; Spark Therapeutics Inc.; Amgen Inc.; Gilead Sciences Inc.; Enzyvant Therapeutics GmbH; Novartis AG; Astellas Pharma, Inc. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Market Trends are Influencing Demand for Gene Therapy?
“Research and Development Activities Leading to Production of Novel Gene Therapy Solutions”
Ongoing research and development (R&D) activities are expected to have a significant influence of the sales of gene testing technologies. Several companies are aiming to build a gene therapy platform with a strategy centered on establishing a transformational portfolio through in-house faculty and enhancing those capabilities through strategic collaborations, R&D expansion, potential licensing, and merger & acquisition activities.
- The Cystic Fibrosis Foundation announced an investment in SalioGen Therapeutics in January 2022 to support the company's preclinical research into novel gene therapy for cystic fibrosis. SalioGen's Gene Coding approach is intended to activate, deactivate, or modify the function of any gene in the genome.
“Rigorous Clinical Trials Leading to Development of Novel Cell and Gene Therapies for Sickle Cell Disease”
For sickle cell disease, previously bone marrow transplant was the only and limited treatment procedure. Sickle cell disease is considered as a lifelong condition causing blockages in the blood vessels. This deadly disease if not treated effectively can lead to organ damages and strokes.
Researchers are highly focusing on the novel treatment procedures for sickle cell disease. The use of gene therapy and CRISPR technology is set to be effective for treating sickle cell disease.
- In 2023, after rigorous clinical trials carried out at Children’s Hospital of Philadelphia (CHOP) the United States Food and Drug Administration approved CASGEVYTM by Vertex Pharmaceuticals Inc. any LYFGENIATM by Bluebird Bio Inc. as first two gene therapies for the sickle cell disease for patients of 12 years and older.
Lyfgenia is a cell-based gene therapy while Casgevy is a type of novel genome editing technology. Thus, introduction of these technologies is representing and innovative advancements in the field of gene therapy.
Which Factors are Limiting Sales of Genealogy Products and Services?
“High Cost of Gene and Cell Therapies”
Gene therapies are expensive medical procedures that necessitate significant capital investment on the part of both the provider and the patient. Gene modifications necessitate precision equipment, which significantly raises the cost of cell and gene therapy and hinders their demand growth. Thus, high treatment cost is leading to the lower adoption of viral vector gene therapies.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Start-up Ecosystem
- StrideBio is a United States-based start-up that provides adeno-associated virus-medicated gene therapy solutions. The start-up’s portfolio includes drugs for genetic conditions such as Reavet Syndrome, Rett syndrome, and Froedrich’s ataxia.
- Generation Bio is an American start-up that offers non-viral gene therapy solutions. The company’s solution uses closed-ended deoxyribonucleic acid (ceDNA) system, which is capable of delivering multiple genes to a cell. The company also offers solutions for retina and liver disorders, which are in pre-clinical development and early stages.
Country-wise Analysis
What is the Demand Outlook for Gene Therapy in the United States?
“Strong Regulatory Frameworks and Positive Reimbursement Policies”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 3.14 Billion |
| Growth Rate (2024 to 2034) | 13.4% CAGR |
| Projected Value (2034F) | US$ 11.05 Billion |
Presence of strong regulatory frameworks for promoting the development of cellular therapy and the existence of major biopharma companies are contributing to the growth of the United States market. The United States government is strongly funding centers and institutes who are engaged in gene therapy research and development efforts. Furthermore, the rising prevalence of chronic diseases, the presence of advanced healthcare infrastructure, and the availability of reimbursement policies are expected to boost the adoption of gene therapies in the coming decade.
Will India Be a Profitable Market to Invest In?
“Investments in R&D to Offer Lucrative Opportunities for Gene Therapy Solution Providers”
| Attribute | India |
|---|---|
| Market Value (2024E) | US$ 569.9 Million |
| Growth Rate (2024 to 2034) | 22.4% CAGR |
| Projected Value (2034F) | US$ 4.30 Billion |
Optimization of vectors such as retroviruses and lentivirus, the introduction of new techniques such as induced pluripotent stem cells in conjunction with current gene editing models, and even trials in germ cells are set to boost the popularity of gene therapies in India over the coming 10 years. Increasing investments in healthcare infrastructure by central government are emerging as a notable gene therapy market trend in India. The country is also witnessing an increase in cancer cases, which is further encouraging the use of gene therapy in oncology treatments.
Which Aspects are Pushing Sales of Gene Therapy Solutions in Germany?
“Strong Presence of Regenerative Medicine Companies”
Germany is the best market for manufacturing cell and gene therapy products in Europe. Germany is at forefront in innovations and healthcare sector is no exception. Europe is home to more than 238 regenerative medicine companies, nearly to a quarter of the world's regenerative medicine therapeutic developers.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Analysis
Which Vector Type is Gaining Traction in This Business Space?
“Adeno-Associated Virus (AVV) Safe and Well-tolerated Vector for Gene Therapy”
| Attribute | Adeno-Associated Virus |
|---|---|
| Segment Value (2024E) | US$ 2.6 Billion |
| Growth Rate (2024 to 2034) | 15.9% CAGR |
| Projected Value (2034F) | US$ 11.37 Billion |
Vector is particularly a particle acting as a vehicle to carry any foreign nucleic sequence usually DNA. Adeno-associated virus (AAV) is gaining high attention as a vector for gene therapy especially in clinical-stage experimental therapeutic strategies. The ability to regenerate recombinant AAV particles lacking any viral genes is proving to be fastest move for gene therapies.
Which Disease is Gene Therapy Widely Used to Treat?
“Effective and Widespread Use of Gene Therapy to Treat Spinal Muscular Atrophy (SMA)”
| Attribute | Spinal Muscular Atrophy (SMA) |
|---|---|
| Segment Value (2024E) | US$ 3.6 Billion |
| Growth Rate (2024 to 2034) | 8.9% CAGR |
| Projected Value (2034F) | US$ 8.43 Billion |
Spinal muscular atrophy (SMA) is a rare disease but very common fatal inherited diseases of infancy. Gene therapies are found to be very effective in treating SMA.
- In 2019 the United States Food and Drug Administration approved onasemnogene abeparvovec, SMN1 gene replacement therapy (brand name Zolgensma), for all children with SMA younger than two years of age.
Zolgensma is a recent advancement in the field of gene therapy to treat spinal muscular atrophy. Zolgensma is administered in a one-time infusion to patients less than 2 years of age.
Competitive Landscape
Some of the key players in the gene therapy market are Amgen Inc., Bluebird Bio, Gilead Sciences, Inc., Novartis AG, Orchard Therapeutics, Sibiono GeneTech Co. Ltd., Spark Therapeutics (Roche AG), and UniQure N.V. To secure a major position in the global market, various strategic alliances such as collaborations, acquisitions, and the launch of advanced products are employed by these industry leaders.
- In October 2021, the National Institutes of Health, the United States Food and Drug Administration, ten pharmaceutical companies, and five non-profit organizations announced a collaboration to accelerate the development of gene therapies for the 30 million Americans who suffer from rare diseases. Such initiatives are expected to boost demand for gene therapies in the coming decade.
- Novartis acquired Gyroscope Therapeutics in December 2021, adding a one-time gene therapy that is expected to transform care for geographic atrophy, a leading cause of blindness.
- Abecma (idecabtagene vicleucel), a cell-based gene therapy, was approved by the United States Food and Drug Administration in March 2021 to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy. Abecma is the first FDA-approved cell-based gene therapy for the treatment of multiple myeloma.
Key Segments of Gene Therapy Market Research
-
By Vector Type :
- Lentivirus
- Adeno-Associated Virus (AAV)
- Retrovirus & Gamma Retrovirus
- Modified Herpes Simplex Virus
- Adenovirus
- Non-Viral Plasmid Vector
- Others
-
By Indication :
- Acute Lymphoblastic Leukemia (ALL)
- Inherited Retinal Disease
- Large B-cell Lymphoma
- ADA-SCID, Melanoma (Lesions)
- Beta-Thalassemia Major/SCD
- Head & Neck Squamous Cell Carcinoma
- Peripheral Arterial Disease
- Spinal Muscular Atrophy (SMA)
- Others
-
By Route of Administration :
- Intravenous
- Others
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Key Success Factors
- 5. Market Background
- 6. Global Market Volume (Units) Analysis 2018 to 2023 and Forecast, 2024 to 2034
- 7. Global Market - Pricing Analysis
- 8. Global Market Value Analysis 2018 to 2023 and Forecast, 2024 to 2034
- 9. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Product
- 9.1. Yescarta
- 9.2. Kymirah
- 9.3. Luxturna
- 9.4. Strimvelis
- 9.5. Gendicine
- 9.6. Others
- 10. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Application
- 10.1. Ophthalmology
- 10.2. Oncology
- 10.3. Adenosine Deaminase/Deficient Severe Combined Immunodeficiency (ADA-SCID)
- 11. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Region
- 11.1. North America
- 11.2. Latin America
- 11.3. Europe
- 11.4. East Asia
- 11.5. South Asia
- 11.6. Oceania
- 11.7. Middle East and Africa (MEA)
- 12. North America Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 13. Latin America Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 14. Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 15. South Asia Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 16. East Asia Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 17. Oceania Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 18. Middle East and Africa Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 19. Key and Emerging Countries Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 20. Market Structure Analysis
- 21. Competition Analysis
- 21.1. Novartis AG
- 21.2. Gilead Sciences Inc.
- 21.3. Spark Therapeutics Inc.
- 21.4. Sibiono GeneTech Co. Ltd.
- 21.5. CELGENE CORPORATION
- 21.6. Orchard Therapeutics Limited
- 21.7. BioNTech
- 22. Assumptions and Acronyms Used
- 23. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Volume (‘000 Units) Analysis and Opportunity Assessment 2018 to 2034, By Product
Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Product
Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Application
Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Region
Table 05: North America Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 06: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Product
Table 07: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Application
Table 08: Latin America Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 09: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Product
Table 10: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Application
Table 11: Europe Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 12: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Product
Table 13: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Application
Table 14: South Asia Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 15: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Product
Table 16: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Application
Table 17: East Asia Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 18: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Product
Table 19: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Application
Table 20: Oceania Market Value (US$ Mn) Analysis 2018 to 2023and Forecast 2024 to 2034, By Country
Table 21: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Product
Table 22: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Application
Table 23: Middle East and Africa Market Value (US$ Mn) Analysis 2018 to 2023and Forecast 2024 to 2034, By Country
Table 24: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Product
Table 25: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Application
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Volume (in 000' Units) Analysis, 2018 to 2023
Figure 02: Global Market Volume Forecast (in 000' Units), 2024 to 2034
Figure 03: Pricing Analysis (US$) Per Product, By Region, 2020
Figure 04: Pricing Analysis (US$) Per Product, By Region, 2020
Figure 05: Global Market Value Analysis (US$ Mn), 2018 to 2023
Figure 06: Global Market Value Forecast (US$ Mn), 2024 to 2034
Figure 07: Global Market Absolute $ Opportunity, 2024 to 2034
Figure 08: Global Market Share Analysis (%), By Product, 2024 to 2034
Figure 09: Global Market Y-o-Y Analysis (%), By Product, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Product, 2024 to 2034
Figure 11: Global Market Share Analysis (%), By Application, 2024 to 2034
Figure 12: Global Market Y-o-Y Analysis (%), By Application, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by Application, 2024 to 2034
Figure 14: Global Market Share Analysis (%), By Region, 2024 to 2034
Figure 15: Global Market Y-o-Y Analysis (%), By Region, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 17: North America Market Value Share, By Product, 2023 (E)
Figure 18: North America Market Value Share, By Application, 2023 (E)
Figure 19: North America Market Value Share, By Country, 2023 (E)
Figure 20: North America Market Value Analysis (US$ Mn), 2018 to 2023
Figure 21: North America Market Value Forecast (US$ Mn), 2024 to 2034
Figure 22: North America Market Attractiveness Analysis by Product, 2024 to 2034
Figure 23: North America Market Attractiveness Analysis by Application, 2024 to 2034
Figure 24: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 25: Latin America Market Value Share, By Product, 2023 (E)
Figure 26: Latin America Market Value Share, By Application, 2023 (E)
Figure 27: Latin America Market Value Share, By Country, 2023 (E)
Figure 28: Latin America Market Value Analysis (US$ Mn), 2018 to 2023
Figure 29: Latin America Market Value Forecast (US$ Mn), 2024 to 2034
Figure 30: Latin America Market Attractiveness Analysis by Product, 2024 to 2034
Figure 31: Latin America Market Attractiveness Analysis by Application, 2024 to 2034
Figure 32: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 33: Europe Market Value Share, By Product, 2023 (E)
Figure 34: Europe Market Value Share, By Application, 2023 (E)
Figure 35: Europe Market Value Share, By Country, 2023 (E)
Figure 36: Europe Market Value Analysis (US$ Mn), 2018 to 2023
Figure 37: Europe Market Value Forecast (US$ Mn), 2024 to 2034
Figure 38: Europe Market Attractiveness Analysis by Product, 2024 to 2034
Figure 39: Europe Market Attractiveness Analysis by Application, 2024 to 2034
Figure 40: Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 41: South Asia Market Value Share, By Product, 2023 (E)
Figure 42: South Asia Market Value Share, By Application, 2023 (E)
Figure 43: South Asia Market Value Share, By Country, 2023 (E)
Figure 44: South Asia Market Value Analysis (US$ Mn), 2018 to 2023
Figure 45: South Asia Market Value Forecast (US$ Mn), 2024 to 2034
Figure 46: South Asia Market Attractiveness Analysis by Product, 2024 to 2034
Figure 47: South Asia Market Attractiveness Analysis by Application, 2024 to 2034
Figure 48: South Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 49: East Asia Market Value Share, By Product, 2023 (E)
Figure 50: East Asia Market Value Share, By Application, 2023 (E)
Figure 51: East Asia Market Value Share, By Country, 2023 (E)
Figure 52: East Asia Market Value Analysis (US$ Mn), 2018 to 2023
Figure 53: East Asia Market Value Forecast (US$ Mn), 2024 to 2034
Figure 54: East Asia Market Attractiveness Analysis by Product, 2024 to 2034
Figure 55: East Asia Market Attractiveness Analysis by Application, 2024 to 2034
Figure 56: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 57: Oceania Market Value Share, By Product, 2023 (E)
Figure 58: Oceania Market Value Share, By Application, 2023 (E)
Figure 59: Oceania Market Value Share, By Country, 2023 (E)
Figure 60: Oceania Market Value Analysis (US$ Mn), 2018 to 2023
Figure 61: Oceania Market Value Forecast (US$ Mn), 2024 to 2034
Figure 62: Oceania Market Attractiveness Analysis by Product, 2024 to 2034
Figure 63: Oceania Market Attractiveness Analysis by Application, 2024 to 2034
Figure 64: Oceania Market Attractiveness Analysis by Country, 2024 to 2034
Figure 65: Middle East and Africa Market Value Share, By Product, 2023 (E)
Figure 66: Middle East and Africa Market Value Share, By Application, 2023 (E)
Figure 67: Middle East and Africa Market Value Share, By Country, 2023 (E)
Figure 68: Middle East and Africa Market Value Analysis (US$ Mn), 2018 to 2023
Figure 69: Middle East and Africa Market Value Forecast (US$ Mn), 2024 to 2034
Figure 70: Middle East and Africa Market Attractiveness Analysis by Product, 2024 to 2034
Figure 71: Middle East and Africa Market Attractiveness Analysis by Application, 2024 to 2034
Figure 72: Middle East and Africa Market Attractiveness Analysis by Country, 2024 to 2034
Figure 73: U. S. Market Value Analysis (US$ Mn), 2024 & 2034
Figure 74: U. S. Market Value Share, By Product, 2023 (E)
Figure 75: U. S. Market Value Share, By Application, 2023 (E)
Figure 76: Canada Market Value Analysis (US$ Mn), 2024 & 2034
Figure 77: Canada Market Value Share, By Product, 2023 (E)
Figure 78: Canada Market Value Share, By Application, 2023 (E)
Figure 79: Mexico Market Value Analysis (US$ Mn), 2024 & 2034
Figure 80: Mexico Market Value Share, By Product, 2023 (E)
Figure 81: Mexico Market Value Share, By Application, 2023 (E)
Figure 82: Brazil Market Value Analysis (US$ Mn), 2024 & 2034
Figure 83: Brazil Market Value Share, By Product, 2023 (E)
Figure 84: Brazil Market Value Share, By Application, 2023 (E)
Figure 85: U. K. Market Value Analysis (US$ Mn), 2024 & 2034
Figure 86: U. K. Market Value Share, By Product, 2023 (E)
Figure 87: U. K. Market Value Share, By Application, 2023 (E)
Figure 88: Germany Market Value Analysis (US$ Mn), 2024 & 2034
Figure 89: Germany Market Value Share, By Product, 2023 (E)
Figure 90: Germany Market Value Share, By Application, 2023 (E)
Figure 91: France Market Value Analysis (US$ Mn), 2024 & 2034
Figure 92: France Market Value Share, By Product, 2023 (E)
Figure 93: France Market Value Share, By Application, 2023 (E)
Figure 94: Italy Market Value Analysis (US$ Mn), 2024 & 2034
Figure 95: Italy Market Value Share, By Product, 2023 (E)
Figure 96: Italy Market Value Share, By Application, 2023 (E)
Figure 97: Spain Market Value Analysis (US$ Mn), 2024 & 2034
Figure 98: Spain Market Value Share, By Product, 2023 (E)
Figure 99: Spain Market Value Share, By Application, 2023 (E)
Figure 100: Russia Market Value Analysis (US$ Mn), 2024 & 2034
Figure 101: Russia Market Value Share, By Product, 2023 (E)
Figure 102: Russia Market Value Share, By Application, 2023 (E)
Figure 103: China Market Value Analysis (US$ Mn), 2024 & 2034
Figure 104: China Market Value Share, By Product, 2023 (E)
Figure 105: China Market Value Share, By Application, 2023 (E)
Figure 106: Japan Market Value Analysis (US$ Mn), 2024 & 2034
Figure 107: Japan Market Value Share, By Product, 2023 (E)
Figure 108: Japan Market Value Share, By Application, 2023 (E)
Figure 109: South Korea Market Value Analysis (US$ Mn), 2024 & 2034
Figure 110: South Korea Market Value Share, By Product, 2023 (E)
Figure 111: South Korea Market Value Share, By Application, 2023 (E)
Figure 112: India Market Value Analysis (US$ Mn), 2024 & 2034
Figure 113: India Market Value Share, By Product, 2023 (E)
Figure 114: India Market Value Share, By Application, 2023 (E)
Figure 115: ASEAN Market Value Analysis (US$ Mn), 2024 & 2034
Figure 116: ASEAN Market Value Share, By Product, 2023 (E)
Figure 117: ASEAN Market Value Share, By Application, 2023 (E)
Figure 118: Australia Market Value Analysis (US$ Mn), 2024 & 2034
Figure 119: Australia Market Value Share, By Product, 2023 (E)
Figure 120: Australia Market Value Share, By Application, 2023 (E)
Figure 121: New Zealand Market Value Analysis (US$ Mn), 2024 & 2034
Figure 122: New Zealand Market Value Share, By Product, 2023 (E)
Figure 123: New Zealand Market Value Share, By Application, 2023 (E)
Figure 124: GCC Countries Market Value Analysis (US$ Mn), 2024 & 2034
Figure 125: GCC Countries Market Value Share, By Product, 2023 (E)
Figure 126: GCC Countries Market Value Share, By Application, 2023 (E)
Figure 127: Turkey Market Value Analysis (US$ Mn), 2024 & 2034
Figure 128: Turkey Market Value Share, By Product, 2023 (E)
Figure 129: Turkey Market Value Share, By Application, 2023 (E)
Figure 130: South Africa Market Value Analysis (US$ Mn), 2024 & 2034
Figure 131: South Africa Market Value Share, By Product, 2023 (E)
Figure 132: South Africa Market Value Share, By Application, 2023 (E)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the gene therapy market in 2024?
The global gene therapy market is evaluated at US$ 10.34 billion in 2024.
How fast is gene therapy demand projected to rise?
Revenue from gene therapy solutions is projected to increase at a CAGR of 14.1% during the next 10 years (2024 to 2034).
How much is the projected market value for gene therapy by 2034?
The market for gene therapy is forecasted to reach US$ 38.52 billion by 2034.
What is the future of gene therapy in South Korea?
Demand for gene therapy in South Korea is anticipated to rise at a CAGR of 17.9% from 2024 to 2034.
What is the scope of gene therapies?
Gene therapies ability to replace defective genes with effective one is increasing its use to treat genetic disorders.
Who are the top 3 providers of gene therapy solutions?
Some of the leading companies include BioMarin, Bluebird Bio Inc., and Orchard Therapeutics Limited.
Gene Therapy Market